Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...

Researchers have found that fewer sessions of higher dose vaginal cuff brachytherapy work just as well as more frequent, lower-dose treatments for endometrial cancer patients.

"Only a patient can really appreciate how much ringing the bell matters. So the day he hung it up, it was the most joyous ...

Lung cancer cases are increasing in people who have never smoked, especially in women, a new study by the World Health ...

Dian Pinto, a 47-year-old resident of Mukamar parish, is currently undergoing treatment at A J Hospital & Research Centre, ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...